TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer

Clin Cancer Res. 2019 Aug 1;25(15):4820-4831. doi: 10.1158/1078-0432.CCR-18-4175. Epub 2019 May 10.

Abstract

Purpose: In multiple oncological settings, expression of the coinhibitory ligand PD-L1 by malignant cells and tumor infiltration by immune cells expressing coinhibitory receptors such as PD-1, CTLA4, LAG-3, or TIM-3 conveys prognostic or predictive information. Conversely, the impact of these features of the tumor microenvironment on disease outcome among high-grade serous carcinoma (HGSC) patients remains controversial.

Experimental design: We harnessed a retrospective cohort of 80 chemotherapy-naïve HGSC patients to investigate PD-L1 expression and tumor infiltration by CD8+ T cells, CD20+ B cells, DC-LAMP+ dendritic cells as well as by PD-1+, CTLA4+, LAG-3+, and TIM-3+ cells in relation with prognosis and function orientation of the tumor microenvironment. IHC data were complemented with transcriptomic and functional studies on a second prospective cohort of freshly resected HGSC samples. In silico analysis of publicly available RNA expression data from 308 HGSC samples was used as a confirmatory approach.

Results: High levels of PD-L1 and high densities of PD-1+ cells in the microenvironment of HGSCs were strongly associated with an immune contexture characterized by a robust TH1 polarization and cytotoxic orientation that enabled superior clinical benefits. Moreover, PD-1+TIM-3+CD8+ T cells presented all features of functional exhaustion and correlated with poor disease outcome. However, although PD-L1 levels and tumor infiltration by TIM-3+ cells improved patient stratification based on the intratumoral abundance of CD8+ T cells, the amount of PD-1+ cells failed to do so.

Conclusions: Our data indicate that PD-L1 and TIM-3 constitute prognostically relevant biomarkers of active and suppressed immune responses against HGSC, respectively.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Aged
  • B7-H1 Antigen / immunology
  • B7-H1 Antigen / metabolism
  • Biomarkers, Tumor / immunology
  • Biomarkers, Tumor / metabolism*
  • CD8-Positive T-Lymphocytes / immunology*
  • CTLA-4 Antigen / immunology
  • CTLA-4 Antigen / metabolism
  • Carcinoma, Ovarian Epithelial / immunology*
  • Carcinoma, Ovarian Epithelial / metabolism
  • Carcinoma, Ovarian Epithelial / pathology
  • Cystadenocarcinoma, Serous / immunology*
  • Cystadenocarcinoma, Serous / metabolism
  • Cystadenocarcinoma, Serous / pathology
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Hepatitis A Virus Cellular Receptor 2 / immunology
  • Hepatitis A Virus Cellular Receptor 2 / metabolism*
  • Humans
  • Lymphocytes, Tumor-Infiltrating / immunology*
  • Lysosomal Membrane Proteins / immunology
  • Lysosomal Membrane Proteins / metabolism
  • Middle Aged
  • Neoplasm Proteins / immunology
  • Neoplasm Proteins / metabolism
  • Prognosis
  • Retrospective Studies
  • Survival Rate

Substances

  • B7-H1 Antigen
  • Biomarkers, Tumor
  • CD274 protein, human
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • HAVCR2 protein, human
  • Hepatitis A Virus Cellular Receptor 2
  • LAMP3 protein, human
  • Lysosomal Membrane Proteins
  • Neoplasm Proteins